Enzymatica has entered into a distribution agreement with ABEX for marketing and sales of ColdZyme® cold spray on the South African market. The product will be launched into the market in late 2018.
ABEX will sell ColdZyme to all major pharmacy chains, independent pharmacies, as well as through non-conventional channels and grocery stores in South Africa. The company plans to launch ColdZyme in late 2018, but with a focus on the 2019 South African winter season, which extends from March to July. The company will conduct an extensive marketing campaign, including advertising in traditional media and in-store advertising, as well as radio commercials and marketing in social media.
The South African cold market is estimated at ZAR 2.1 billion, corresponding to about SEK 1.4 billion. Most cold preparations provide symptomatic relief and only a few cold sprays focus on the cold virus. Consequently, ABEX sees great opportunities to position ColdZyme as an extremely interesting treatment option within the segment.
"We are extremely proud of our collaboration with Enzymatica and the opportunity to be responsible for introducing ColdZyme to the market. With the lack of new clinically proven treatment options in the local market, there is huge potential for ColdZyme to become a trusted household brand for consumers, which can be used both as a preventative option as well as to reduce the duration of colds," says Ed Hallam, who is responsible for commercial operations at ABEX.
"We are extremely pleased about the agreement with ABEX, which is a well-established and highly respected pharmaceutical company with a strong distribution network in the South African market," says Fredrik Lindberg, CEO of Enzymatica.
ABEX Pharmaceutica is a privately owned pharmaceutical company that was founded in 2006 and has its headquarters in Port Elizabeth, along with sales and technology offices in Pretoria. The company also has representation offices in China, Hong Kong, Australia and the United Kingdom. ABEX develops, manufactures and sells both pharmaceuticals and over the counter (OTC) products, as well as medical devices. The company has a total of about 30 direct and indirect employees.
For more information, please contact:
Fredrik Lindberg, CEO, Enzymatica AB
Tel: +46 (0)708-86 53 70 | Email: firstname.lastname@example.org
Carl-Johan Wachtmeister, Head of Corporate Communications, Enzymatica AB
Tel: +46 (0)701-88 50 21 | Email: email@example.com
About Enzymatica AB
Enzymatica AB is a Swedish life science company that develops and sells medical devices for infection-related diseases. The products are based on a barrier technology that includes marine enzymes. The company's first product is ColdZyme® Mouth Spray, which can prevent colds and reduce the duration of disease. The product has been launched in about ten markets. The strategy is to continue to grow by strengthening the Company's position in existing markets and expanding into new geographic markets through established partners. The company has its headquarters in Lund and is listed on Nasdaq First North. For more information, visit: www.enzymatica.com
Enzymatica's certified adviser is Erik Penser Bank.För mer information, kontakta:
Enzymaticas Certified Adviser är Erik Penser Bank